exRNAdisease

General Information

Database ID:

exR0089301

RNA Name:

hsa-miR-665

RNA Type:

miRNA

Chromosome:

chr14

Starnd:

Coordinate:

Start Site(bp):

100875075

End Site(bp):

100875094

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
GINS1	chr20	25407673	25452628	+
TMED10	chr14	75131469	75176612	-
C19orf12	chr19	29698886	29715789	-
STX6	chr1	180972712	181023121	-
CTSD	chr11	1752755	1764573	-
CCNF	chr16	2429394	2458854	+
GREB1	chr2	11482341	11642788	+
IRF4	chr6	391752	411443	+
COX8A	chr11	63974620	63976543	+
ABHD2	chr15	89087459	89202355	+
CLDN11	chr3	170418865	170454733	+
ZNF527	chr19	37371061	37393066	+
ZBTB7A	chr19	4043303	4066899	-
TAF5L	chr1	229593111	229626047	-
CIPC	chr14	77098126	77117287	+
C6orf120	chr6	169702190	169704856	+
HADHA	chr2	26190635	26244672	-
EXOSC6	chr16	70246778	70251940	-
TSPAN4	chr11	842812	867116	+
EHD2	chr19	47713422	47743134	+
KLHDC3	chr6	43014103	43021298	+
CACUL1	chr10	118674167	118755249	-
RBM33	chr7	155644451	155781485	+
GUCD1	chr22	24540423	24555935	-
ELN	chr7	74027789	74069907	+
RHOF	chr12	121777754	121803403	-
VMA21	chrX	151396515	151409364	+
CBFB	chr16	67028984	67101058	+
STX3	chr11	59713456	59805882	+
TNFRSF1B	chr1	12166991	12209228	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000417	chr12	69644908	69656342	+
hsa_circ_0000402	chr12	53670403	53671011	+
hsa_circ_0000798	chr17	65941524	65944422	+
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0001387	chr4	1902352	1936989	+
hsa_circ_0000799	chr17	65941524	65972074	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC005394.2	chr19	28435388	28727680	-
AC018521.1	chr17	47945424	47981736	+
AC023509.1	chr12	53441741	53467528	+
AC118758.3	chr7	56809214	56848800	-
AC234582.1	chr1	155195004	155205495	+
AL355987.4	chr9	136799223	136810042	+
ARHGAP27P1-BPTFP1-KPNA2P3	chr17	64749663	64781707	-
LINC00665	chr19	36313067	36331770	-
LINC00910	chr17	43338741	43389199	-
LINC01089	chr12	121795267	121803906	-
LINC01535	chr19	37251885	37265535	+
MIR29B2CHG	chr1	207801518	207879115	-
MIR497HG	chr17	7015818	7019659	-
NEAT1	chr11	65422774	65445540	+
OIP5-AS1	chr15	41283990	41309737	+
SND1-IT1	chr7	127997597	128000077	+
SNHG16	chr17	76557764	76565348	+
STAG3L5P-PVRIG2P-PILRB	chr7	100336104	100367831	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.